Evidence map›Paper›PMID 33807854›Full record

ArticleInternational journal of molecular sciences2021

Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.

Chunguang Liang, Elena Bencurova, Eric Psota, Priya Neurgaonkar, Martina Prelog, Carsten Scheller, Thomas Dandekar

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chunguang LiangDepartment of Bioinformatics, Biocenter, Am Hubland, University of Würzburg, 97074 Würzburg, Germany.
Elena BencurovaDepartment of Bioinformatics, Biocenter, Am Hubland, University of Würzburg, 97074 Würzburg, Germany.ORCID 0000-0003-4268-1812
Eric PsotaDepartment of Pediatrics, Rheumatology and Special Immunology, University Hospital Würzburg, Pediatric Rheumatology/Special Immunology, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.ORCID 0000-0001-5733-7980
Priya NeurgaonkarDepartment of Bioinformatics, Biocenter, Am Hubland, University of Würzburg, 97074 Würzburg, Germany.
Martina PrelogDepartment of Pediatrics, Rheumatology and Special Immunology, University Hospital Würzburg, Pediatric Rheumatology/Special Immunology, Josef-Schneider-Str. 2, 97080 Würzburg, Germany.
Carsten SchellerInstitute of Virology and Immunobiology, University of Würzburg, Versbacher Str. 7, 97078 Würzburg, Germany.ORCID 0000-0002-0367-1905
Thomas DandekarDepartment of Bioinformatics, Biocenter, Am Hubland, University of Würzburg, 97074 Würzburg, Germany.ORCID 0000-0003-1886-7625

Funding

Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst contribution to our DFG project 324392634-TRR 221/INF
6 · The paper itself

Abstract

We observed substantial differences in predicted Major Histocompatibility Complex II (MHCII) epitope presentation of SARS-CoV-2 proteins for different populations but only minor differences in predicted MHCI epitope presentation. A comparison of this predicted epitope MHC-coverage revealed for the early phase of infection spread (till day 15 after reaching 128 observed infection cases) highly significant negative correlations with the case fatality rate. Specifically, this was observed in different populations for MHC class II presentation of the viral spike protein (

Indexed as

Adaptive ImmunityAllelesComputational BiologyCorrelation of DataCOVID-19Epitopes, B-LymphocyteEpitopes, T-LymphocyteHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansMortalitySARS-CoV-2Viral Structural ProteinsEpitopes, B-LymphocyteEpitopes, T-LymphocyteHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensViral Structural ProteinsB-cellCOVID-19epitope mappinginfection spreadlethality rateMHC IMHC IIpopulation coverageSARS-CoV-2T-cell

Identifiers

PMID33807854
PMCPMC7961590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.